Gaining expertise in the application of the SBP-6-IMNs requires time and guidance. This Website will provide guidance by answering questions by email. When the answer serves the medical practitioners at large, the questions and answers will be listed in the Website for access by those who are interested.

Autoimmune Diseases such as Lupus Nephritis (LN), Rheumatoid Factor Positive (RF+) Rheumatoid Arthritis (RA), and NSAID-refractory Ankylosing Spondylitis (Nr-AS) have never been satisfactory treated since the 1950s. Outcomes since the 1950s up to the therapy of these autoimmune diseases with Biologic Response Modifiers since the 2000s are dismally disappointing.

It is only with the Step-down Bridge Protocol of Intravenous and Oral
Combination of 6 Immunosuppressants (SBP-6-IMNs or JD Protocol) that outcomes are satisfactory since the 1990s. Induction of Remission by intravenous therapy takes only 2 – 4 months. Tapering off intravenous therapy takes only 5.5-7.5 months. After that oral drugs maintain Remission. Needless to say that the JD Protocol was created based on more than 10 years research by trials and errors.

My Vision is to see the Rheumatology Communities or rheumatologists and medical practitioners apply the JD Protocol to these autoimmune diseases. Short, medium, and long-term outcome should be satisfactory to the patients and the attending rheumatologists.

Through this website you will find the refutation of Mitoses on LN, RF+ RA, and Nr-AS by the JD Protocol. You will also find how these outcomes are achieved. Under menu Medical Info there are a lot of medical information about the breakthrough in the treatment of almost all autoimmune diseases.

My mission is to spread the application of the JD Protocol around the world among the rheumatologists and medical Practitioners. For this reasons a RF+ RA Workshop has been held during the APLAR Congress, September 2004, in Jeyu, Korea.

The outcome of the treatment of RF+ RA with the Step-down Bridge Protocol of Intravenous and Oral Combination of 5 Immunosuppressants will be presented at the WHO-ILAR Bone and Joint Decade Symposium, June 11-12, 2005, Viena, Austria. A Therapy Workshop on the Outcome of the Treatment of NSAID-refractory Ankylosing Spondylitis with the JD Protocol will be held in October, 2005, Dhaka, Bangladesh. A similar Therapy Workshop will be held during the APLAR Congress, August 2006, in Kuala Lumpur, Malaysia.

Regards,

John Darmawan, MD, PhD
WHO Expert on the Rheumatic Diseases,
Semarang, Indonesia.

What is Rheumatology Preceptorship in DMARDs refractory Rheumatoid Arthritis (RA)?

The primary health care physicians (general practitioners or family physicians) bring 1 or 2 of his/her patients for training in infusion and polyarticular injections techniques. They should bring the worst case of RA in a wheelchair or with crutches or walker. If these DMARDs refractory RA patients are brought into remission within 2 months by a trainee (released from a wheel chair or walker, or crutches) then she/he should have no trouble in treating and managing less severe RA patients.

  Email This Page   Print This Page